IRIS Accounts Production v23.3.0.418 11899646 director 1.4.22 31.3.23 31.3.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh118996462022-03-31118996462023-03-31118996462022-04-012023-03-31118996462021-03-31118996462021-04-012022-03-31118996462022-03-3111899646ns10:Originalns15:EnglandWales2022-04-012023-03-3111899646ns14:PoundSterlingns10:Original2022-04-012023-03-3111899646ns10:Originalns10:Director12022-04-012023-03-3111899646ns10:Original2022-04-012023-03-3111899646ns10:Original2023-03-3111899646ns10:Originalns10:PrivateLimitedCompanyLtd2022-04-012023-03-3111899646ns10:Originalns10:SmallEntities2022-04-012023-03-3111899646ns10:Originalns10:AuditExempt-NoAccountantsReport2022-04-012023-03-3111899646ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-04-012023-03-3111899646ns10:SmallCompaniesRegimeForAccountsns10:Original2022-04-012023-03-3111899646ns10:Originalns10:FullAccounts2022-04-012023-03-3111899646ns10:Originalns10:OrdinaryShareClass12022-04-012023-03-3111899646ns10:CompanySecretary1ns10:Original2022-04-012023-03-3111899646ns10:Originalns10:RegisteredOffice2022-04-012023-03-3111899646ns10:Original2022-03-3111899646ns10:Originalns5:CurrentFinancialInstruments2023-03-3111899646ns10:Originalns5:CurrentFinancialInstruments2022-03-3111899646ns10:Originalns5:Non-currentFinancialInstruments2023-03-3111899646ns10:Originalns5:Non-currentFinancialInstruments2022-03-3111899646ns5:ShareCapitalns10:Original2023-03-3111899646ns5:ShareCapitalns10:Original2022-03-3111899646ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-03-3111899646ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-03-3111899646ns10:Originalns5:FurnitureFittings2022-04-012023-03-3111899646ns10:Originalns5:MotorVehicles2022-04-012023-03-3111899646ns10:Originalns5:ComputerEquipment2022-04-012023-03-3111899646ns10:Original2021-04-012022-03-3111899646ns10:Originalns5:FurnitureFittings2022-03-3111899646ns10:Originalns5:MotorVehicles2022-03-3111899646ns10:Originalns5:ComputerEquipment2022-03-3111899646ns10:Original2022-03-3111899646ns10:Originalns5:FurnitureFittings2023-03-3111899646ns10:Originalns5:MotorVehicles2023-03-3111899646ns10:Originalns5:ComputerEquipment2023-03-3111899646ns10:Originalns5:FurnitureFittings2022-03-3111899646ns10:Originalns5:MotorVehicles2022-03-3111899646ns10:Originalns5:ComputerEquipment2022-03-3111899646ns10:Originalns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2022-03-3111899646ns10:Originalns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2022-04-012023-03-3111899646ns10:Originalns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2023-03-3111899646ns10:Originalns5:MotorVehiclesns5:LeasedAssetsHeldAsLessee2022-03-3111899646ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-03-3111899646ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-03-3111899646ns10:Originalns10:OrdinaryShareClass12023-03-31
REGISTERED NUMBER: 11899646 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 March 2023

for

HL Pharma Ltd

HL Pharma Ltd (Registered number: 11899646)






Contents of the Financial Statements
for the Year Ended 31 March 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


HL Pharma Ltd

Company Information
for the Year Ended 31 March 2023







DIRECTOR: H J Heng





SECRETARY: H J Heng





REGISTERED OFFICE: 8 Maccowan Avenue
Snodland
Kent
ME6 5SU





REGISTERED NUMBER: 11899646 (England and Wales)





ACCOUNTANTS: GiLon
Chartered Certified Accountants
6 Chislett Row
Chelmsford
Essex
CM2 9QS

HL Pharma Ltd (Registered number: 11899646)

Balance Sheet
31 March 2023

31.3.23 31.3.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 50,170 59,122

CURRENT ASSETS
Debtors 5 7,225 11,474
Cash at bank 24,810 20,180
32,035 31,654
CREDITORS
Amounts falling due within one year 6 8,617 17,124
NET CURRENT ASSETS 23,418 14,530
TOTAL ASSETS LESS CURRENT
LIABILITIES

73,588

73,652

CREDITORS
Amounts falling due after more than one year 7 39,204 44,642
NET ASSETS 34,384 29,010

CAPITAL AND RESERVES
Called up share capital 8 10 10
Retained earnings 34,374 29,000
SHAREHOLDERS' FUNDS 34,384 29,010

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

HL Pharma Ltd (Registered number: 11899646)

Balance Sheet - continued
31 March 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 31 October 2023 and were signed by:





H J Heng - Director


HL Pharma Ltd (Registered number: 11899646)

Notes to the Financial Statements
for the Year Ended 31 March 2023

1. STATUTORY INFORMATION

HL Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Fixtures and fittings - 25% on reducing balance
Motor vehicles - 15% on reducing balance
Computer equipment - 25% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

HL Pharma Ltd (Registered number: 11899646)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 April 2022 1,330 58,390 950 60,670
Additions 206 - - 206
At 31 March 2023 1,536 58,390 950 60,876
DEPRECIATION
At 1 April 2022 55 1,216 277 1,548
Charge for year 344 8,576 238 9,158
At 31 March 2023 399 9,792 515 10,706
NET BOOK VALUE
At 31 March 2023 1,137 48,598 435 50,170
At 31 March 2022 1,275 57,174 673 59,122

Fixed assets, included in the above, which are held under finance leases are as follows:
Motor
vehicles
£   
COST
At 1 April 2022
and 31 March 2023 52,590
DEPRECIATION
At 1 April 2022 1,216
Charge for year 8,576
At 31 March 2023 9,792
NET BOOK VALUE
At 31 March 2023 42,798
At 31 March 2022 51,374

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Other debtors 7,225 11,474

HL Pharma Ltd (Registered number: 11899646)

Notes to the Financial Statements - continued
for the Year Ended 31 March 2023

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.3.23 31.3.22
£    £   
Finance leases 5,623 5,807
Trade creditors - 122
Taxation and social security 2,152 3
Other creditors 842 11,192
8,617 17,124

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.3.23 31.3.22
£    £   
Finance leases 39,204 44,642

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.23 31.3.22
value: £    £   
10 Ordinary 1 10 10

9. RELATED PARTY DISCLOSURES

At the balance sheet date the balance due to the directors was £92 (2021 - £10,442).